Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer

Abstract Tissue kallikrein (hK1) and plasma kallikrein (PK, hKB1) are serine proteases that produce biologically active kinin peptides from endogenous kininogen substrates. There is evidence linking the kallikreins and the mitogenic kinin peptides to carcinogenesis. The aim of this study was to investigate the expression of tissue prokallikrein (pro-hK1), plasma prekallikrein (PPK, pre-hKB1) and kinin B1 and B2 receptor proteins in different subtypes of lung cancer. Immunohistochemistry, using specific antibodies, was performed on archived normal lung sections and sections from adenocarcinomas, squamous cell carcinomas, large cell carcinomas, small cell carcinomas and carcinoid tumours of the lung. Immunoperoxidase labelling was visualised by brightfield microscopy and immunofluorescence labelling by confocal microscopy. Extensive cytoplasmic expression of pro-hK1 and PPK was observed, which was similar in small cell and non-small cell tumours. However, nuclear labelling for the kallikreins was absent or limited. The kinin B1 and B2 receptors were highly expressed in the cytoplasm of all tumour types and in the nuclei of non-small cell tumours. Further studies are required to assess the functional significance of the expression of hK1, PK and kinin receptors in lung tumours, and whether any of these proteins may be potential biomarkers for specific subtypes of lung carcinoma.

[1]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Stewart,et al.  Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Z. Dlamini,et al.  Kallikrein and Kinin Receptor Expression in Inflammation and Cancer , 2001, Biological chemistry.

[4]  E. Diamandis,et al.  Human tissue kallikrein gene family: applications in cancer. , 2005, Cancer letters.

[5]  C. Craik,et al.  A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation , 2001, Nature Cell Biology.

[6]  J. Stockman,et al.  Mortality in Relation to Smoking: 50 Years' Observations on Male British Doctors , 2006 .

[7]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[8]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[9]  L. Chao,et al.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. , 2001, The American journal of pathology.

[10]  E. York,et al.  New lung cancer drugs from bradykinin antagonists. , 2004, Chest.

[11]  C. Figueroa,et al.  Characterization of a tissue kallikrein in human prolactin-secreting adenomas. , 1990, The Journal of endocrinology.

[12]  Richard Doll,et al.  Mortality in relation to smoking: 22 years' observations on female British doctors. , 1980, British medical journal.

[13]  P. Thompson,et al.  Current status of tissue kallikrein inhibitors: importance in cancer. , 2007, Current opinion in investigational drugs.

[14]  J. Stewart,et al.  Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[16]  K. Bhoola,et al.  Assembly of contact-phase factors on the surface of the human neutrophil membrane. , 1994, Blood.

[17]  J. Minna,et al.  Molecular genetics of lung cancer. , 1988, Annual review of medicine.

[18]  D. Kirchhofer,et al.  Unusual Proteolytic Activation of Pro-hepatocyte Growth Factor by Plasma Kallikrein and Coagulation Factor XIa* , 2002, The Journal of Biological Chemistry.

[19]  S. Kojima,et al.  Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. , 2002, Gastroenterology.

[20]  M. Haasemann,et al.  Distribution of bradykinin B2 receptors in target cells of kinin action. Visualization of the receptor protein in A431 cells, neutrophils and kidney sections. , 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[21]  K. Bhoola,et al.  Kallikrein and kinin receptor genes. , 2000, Pharmacology & therapeutics.

[22]  Tetsurou Yamamoto,et al.  Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue , 1988, Japanese journal of cancer research : Gann.

[23]  R Doll,et al.  Mortality in relation to smoking: 40 years' observations on male British doctors , 1994, BMJ.

[24]  P. Thompson,et al.  Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma , 2007, Biological chemistry.

[25]  H. Tschesche,et al.  Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. , 1989, Advances in experimental medicine and biology.

[26]  P. Neth,et al.  The mRNAs of Prekallikrein, Factors XI and XII, and Kininogen, Components of the Contact Phase Cascade Are Differentially Expressed in Multiple Non-hepatic Human Tissues , 2001, Thrombosis and Haemostasis.

[27]  K. Bhoola,et al.  Immunoreactive B1 receptors in human transbronchial tissue. , 1996, Immunopharmacology.

[28]  H. Maeda,et al.  Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues , 2002, International journal of cancer.

[29]  K. Bhoola,et al.  Cellular expression of plasma prekallikrein in human tissues , 2007, Biological chemistry.

[30]  K. Bhoola,et al.  Expression of Tissue Kallikrein and Kinin Receptors in Angiogenic Microvascular Endothelial Cells , 2000, Biological chemistry.

[31]  K. Bhoola,et al.  Visualisation of transforming growth factor-β1, tissue kallikrein, and kinin and transforming growth factor-β receptors on human clear-cell renal carcinoma cells , 2005 .

[32]  K. Bhoola,et al.  Kallikrein-Kinin Cascade , 2006 .

[33]  J. Clements,et al.  The Expanded Human Kallikrein (KLK) Gene Family: Genomic Organisation, Tissue-Specific Expression and Potential Functions , 2001, Biological chemistry.

[34]  Richard Doll,et al.  The Mortality of Doctors in Relation to Their Smoking Habits , 1954, British medical journal.

[35]  Z. Dlamini,et al.  Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. , 1999, Immunopharmacology.

[36]  Miltiadis Paliouras,et al.  Human tissue kallikreins: the cancer biomarker family. , 2007, Cancer letters.

[37]  P. Thompson,et al.  Expression of kallikrein-related peptidases (KRP/hK5, 7, 6, 8) in subtypes of human lung carcinoma. , 2008, International immunopharmacology.

[38]  P. Boffetta.  Epidemiology of environmental and occupational cancer , 2004, Oncogene.

[39]  K. Bhoola,et al.  Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. , 2001, International immunopharmacology.

[40]  K. Bhoola,et al.  Kinin receptors are expressed in human astrocytic tumour cells. , 1999, Immunopharmacology.

[41]  K. Bhoola,et al.  Localization of proteases and peptide receptors by confocal microscopy. , 1999, Methods in enzymology.

[42]  W. Gullick,et al.  Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. , 1989, Journal of cell science.

[43]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[44]  W. Franklin,et al.  Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. , 2000, Chest.

[45]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[46]  Steven R. Williams,et al.  Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein* , 2005, Journal of Biological Chemistry.

[47]  W. Kisiel,et al.  Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung , 1987, Cancer.

[48]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[49]  J. Clements,et al.  The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers , 2004, Critical reviews in clinical laboratory sciences.

[50]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[51]  C. Planque,et al.  Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues , 2006, Biological chemistry.

[52]  E. Diamandis,et al.  Cellular distribution of human tissue kallikreins: immunohistochemical localization , 2006, Biological chemistry.

[53]  Z. Dlamini,et al.  Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma , 2005, Journal of Clinical Pathology.

[54]  E. G. Erdös,et al.  Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. , 2000, Molecular pharmacology.